ReviewHarm reduction journal2022
Can alternative nicotine products put the final nail in the smoking coffin?
Review in Harm reduction journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential of new nicotine and tobacco products as tools for people who smoke to quit combustible cigarettes - a systematic review of common practices and guidance towards a robust study protocol to measure cessation efficacy.Harm reduction journal · 2024Pooled it
- Transformation of the tobacco product market in Japan, 2011-2023.Tobacco control · 2026Article
- Joinpoint trend analysis of prevalence of combustible and non-combustible tobacco product use by adults in the United States, using cross-sectional data from NHIS 2015-2023.Tobacco induced diseases · 2026Article
- Article
- Delphi consensus methodology to gauge expert perspectives on smoking prevention, cessation and harm reduction in Italy.Frontiers in psychiatry · 2025Review
- Socioeconomic status and its limited influence on perceptions of heated tobacco products and cigarettes: no relation with physical health, but association with mental health benefits and lower sensitivity to peer pressure.Frontiers in public health · 2025Article
- The Interplay of Tobacco Farming and Tobacco Control: Exploring Socioeconomic and Health Dynamics in Malawi.Public health challenges · 2024Article
- Is smokeless tobacco a healthier option in patients with AUD? A follow-up study during treatment.Harm reduction journal · 2024Article
- A Global Health Survey of People Who Vape but Never Smoked: Protocol for the VERITAS (Vaping Effects: Real-World International Surveillance) Study.JMIR research protocols · 2024Article
- Future nicotine use preferences of current cigarette smokers: Findings from the 2020 International Tobacco Control Four Country Smoking and Vaping Survey.Drug and alcohol review · 2024Article
- Perceptions, intentions, and actual use of a consumer nicotine gum.Harm reduction journal · 2023Article
- An Analysis of Nicotine Pouch Use by Middle School and High School Students Surveyed by the National Youth Tobacco Survey in 2021 and a Review of the Literature.Journal of primary care & community healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review describes the evolution of smoking prevalence in countries with relatively high adoption of alternative nicotine products such as e-cigarettes, heated tobacco, and snus compared to neighboring countries where these products are less prevalent. The data indicate that countries with high adoption of alternative nicotine products have been able to achieve lower smoking rates. The findings suggest that adoption of alternative nicotine products may help in reduce smoking prevalence faster than traditional tobacco control measures solely focused on prevention and cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.